Canary Applied Intelligence INC (Canary AI), a US-India healthcare AI company focused on kidney disease, has been selected for the February 2026 cohort of the Mayo Clinic Platform Accelerate program, where the company is developing predictive clinical models within Mayo Clinic Platform’s federated environment using de-identified patient data.
Kidney disease populations experience some of the highest hospital readmission rates in healthcare, particularly across chronic kidney disease (CKD), dialysis, and transplant care. Delayed recognition of clinical deterioration frequently contributes to emergency visits, hospitalization, and poor long-term outcomes.
Canary AI is focused on developing technologies that identify early signs of deterioration and support more proactive patient management after discharge, with the goal of helping hospitals and care teams intervene earlier in high-risk kidney populations. The company’s broader focus includes supporting discharge planning and post-discharge care coordination for patients at elevated risk of readmission and clinical deterioration.
The company is led by co-founders Kaushik Suresh and Ajay Bharadwaj, whose backgrounds span biosensing, wearable monitoring, edge computing, quantitative risk systems, and predictive infrastructure.
“We believe kidney care is moving toward proactive and longitudinal monitoring,” said Kaushik Suresh, co-founder of Canary AI. “Many readmissions across CKD and dialysis populations may be avoidable when clinicians can identify deterioration patterns earlier. Our goal is to support hospitals and care teams with technologies that enable earlier intervention and continuity of care.”
Kaushik has led the development of wearable monitoring technologies focused on kidney deterioration and fluid overload management, including systems integrating bio-impedance, ECG, PPG, and physiological monitoring for longitudinal patient assessment. Canary AI has also received Ethics Committee Clearance in India for clinical studies evaluating wearable physiological signals alongside chest CT imaging and cardiovascular measurements in kidney and cardiac patients.
Ajay Bharadwaj, co-founder of Canary AI, brings experience across quantitative risk systems, edge AI infrastructure, and predictive modeling. Prior to Canary AI, he worked on early PyTorch Mobile and edge deployment infrastructure at Samsung and later contributed to predictive risk infrastructure at CreditSights, a Fitch Group company. He also co-founded Veracity Ventures, where he developed predictive infrastructure and automated modeling systems across complex financial environments. At Canary AI, he is applying this background in longitudinal risk modeling and quantitative systems to healthcare, focusing on kidney deterioration, readmission risk, and remote patient monitoring.
“At Canary AI, we’re drawing from advances in quantitative risk modeling and multimodal modeling to address healthcare problems where earlier detection can support improved patient management,” said Ajay Bharadwaj. “Kidney disease patients generate complex clinical, physiological, and longitudinal data over time, and we believe combining these signals can help uncover deterioration patterns that are difficult to identify through conventional workflows alone.”
Within Mayo Clinic Platform Accelerate, Canary AI is developing models focused on kidney-related deterioration and readmission risk using multimodal clinical data in Mayo Clinic Platform’s federated environment. The company is also engaging with Mayo Clinic experts and clinicians to refine the clinical relevance and potential deployment pathways of its technologies.
Since inception, Canary AI and its founders have received more than INR 2.2 Crores (approximately USD 227,000+) in non-dilutive grants and innovation funding from Indian organizations including the Indian Council of Medical Research (ICMR) First in the World Challenge, BIRAC BIG, IITM Pravartak, and the Novo Nordisk–FITT Healthier India Challenge, along with in-kind support from Mayo Clinic Platform Accelerate.
Canary Applied Intelligence INC (Canary AI) is a US-India healthcare technology company developing predictive AI technologies and remote monitoring systems focused on chronic kidney disease, dialysis, and transplant care. The company is focused on supporting earlier intervention, proactive monitoring, and improved care coordination across high-risk kidney populations.
